463 related articles for article (PubMed ID: 10215696)
1. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
Working PK; Newman MS; Sullivan T; Yarrington J
J Pharmacol Exp Ther; 1999 May; 289(2):1128-33. PubMed ID: 10215696
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
Saad SY; Najjar TA; Alashari M
J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
[TBL] [Abstract][Full Text] [Related]
3. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model.
Vail DM; Chun R; Thamm DH; Garrett LD; Cooley AJ; Obradovich JE
Clin Cancer Res; 1998 Jun; 4(6):1567-71. PubMed ID: 9626479
[TBL] [Abstract][Full Text] [Related]
5. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.
Forrest GL; Gonzalez B; Tseng W; Li X; Mann J
Cancer Res; 2000 Sep; 60(18):5158-64. PubMed ID: 11016643
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice.
Bruynzeel AM; Vormer-Bonne S; Bast A; Niessen HW; van der Vijgh WJ
Cancer Chemother Pharmacol; 2007 Sep; 60(4):509-14. PubMed ID: 17177067
[TBL] [Abstract][Full Text] [Related]
7. Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity.
Zou Y; Priebe W; Stephens LC; Perez-Soler R
Clin Cancer Res; 1995 Nov; 1(11):1369-74. PubMed ID: 9815933
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart.
Sun X; Zhou Z; Kang YJ
Cancer Res; 2001 Apr; 61(8):3382-7. PubMed ID: 11309296
[TBL] [Abstract][Full Text] [Related]
9. Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration.
Gabizon A; Meshorer A; Barenholz Y
J Natl Cancer Inst; 1986 Aug; 77(2):459-69. PubMed ID: 3461207
[TBL] [Abstract][Full Text] [Related]
10. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
[TBL] [Abstract][Full Text] [Related]
11. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation.
Herman EH; Rahman A; Ferrans VJ; Vick JA; Schein PS
Cancer Res; 1983 Nov; 43(11):5427-32. PubMed ID: 6616474
[TBL] [Abstract][Full Text] [Related]
12. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
Mohamed HE; Asker ME; Ali SI; el-Fattah TM
J Pharm Pharmacol; 2004 Jun; 56(6):757-68. PubMed ID: 15231041
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
Jaenke RS; Deprez-DeCampeneere D; Trouet A
Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
[TBL] [Abstract][Full Text] [Related]
14. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
[TBL] [Abstract][Full Text] [Related]
15. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?
Theodoulou M; Hudis C
Cancer; 2004 May; 100(10):2052-63. PubMed ID: 15139046
[TBL] [Abstract][Full Text] [Related]
16. Morphine is protective against doxorubicin-induced cardiotoxicity in rat.
Kelishomi RB; Ejtemaeemehr S; Tavangar SM; Rahimian R; Mobarakeh JI; Dehpour AR
Toxicology; 2008 Jan; 243(1-2):96-104. PubMed ID: 17988779
[TBL] [Abstract][Full Text] [Related]
17. Influence of carnosine on the cardiotoxicity of doxorubicin in rabbits.
Zieba R; Wagrowska-Danilewicz M
Pol J Pharmacol; 2003; 55(6):1079-87. PubMed ID: 14730104
[TBL] [Abstract][Full Text] [Related]
18. Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its Antineoplastic activity.
Jagetia GC; Reddy TK; Malagi KJ; Nayak BS; Naidu MB; Ravikiran PB; Kamath SU; Shetty PC; Reddy DS
Phytother Res; 2005 Sep; 19(9):772-8. PubMed ID: 16220569
[TBL] [Abstract][Full Text] [Related]
19. The effect of mitoxantrone treatment in beagle dogs previously treated with minimally cardiotoxic doses of doxorubicin.
Tham P; Dougherty W; Iatropoulos MJ; Gordon G; James VC; Hall C; Noble JF
Am J Pathol; 1987 Jul; 128(1):121-30. PubMed ID: 3605309
[TBL] [Abstract][Full Text] [Related]
20. New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity.
El-Demerdash E; Ali AA; Sayed-Ahmed MM; Osman AM
Cancer Chemother Pharmacol; 2003 Nov; 52(5):411-6. PubMed ID: 12879278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
